Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2024-11-27 00:00:00 ET · period of report 2024-11-25 · accession 0001104659-24-123806 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-27 | 2024-11-25 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $21.58 | +1,727 | 429.9K | +0.4% | +$37.3K |
| DM | 2024-11-27 | 2024-11-25+ | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | S - Sale+OE | $46.81 | -100.0K | 435.2K | -19% | -$4.68M |
| D | 2024-11-27 | 2024-11-25 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | G - Gift | $0.00 | -7,000 | 428.2K | -2% | $0 |
| D | 2024-11-27 | 2024-11-25 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $0.00 | -1,727 | 318.3K | -0.5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-25 | M | A | 1,727 | $21.58 | 429,935 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-26 | S | D | 21,480 | $46.25 | 408,455 | D | — | — | (F4) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.49 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-11-25 | S | D | 78,520 | $46.96 | 435,208 | D | — | — | (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $46.50 to $47.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes an aggregate of 313 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2024. |
| 4 | Common | Common Stock | 2024-11-25 | G | D | 7,000 | $0.00 | 428,208 | D | — | — | |
| 5 | Derivative | Stock Option (right to buy) | 2024-11-25 | M | D | 1,727 | $0.00 | 318,273 | D | $21.58 · — to 2026-10-11 | 1,727 Common Stock | (F5) These stock options are fully vested. |